Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: A case series

A. Fagotti, M. Petrillo, B. Costantini, F. Fanfani, V. Gallotta, V. Chiantera, L. C. Turco, C. Bottoni, G. Scambia

Research output: Contribution to journalArticle

Abstract

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse received SCS + HIPEC during a 4-year period. Among them, 10 cases (11.9%) showed isolated relapse and were treated with laparoscopic/robotic SCS + HIPEC. In all cases complete debulking was achieved. In HIPEC treatment, 9 women received cisplatin at 75 mg/m2, and the remaining patient oxaliplatin 460 mg/m2. In 7 patients SCS was performed through the laparoscopic route, and in 3 cases with a robotic approach. The median operative time from skin incision to the end of cytoreductive surgery was 122 min (95-140), estimated blood loss was 50 cm3 (50-100), and the median length of hospital stay was 4 days (3-7). The interval from surgery to adjuvant chemotherapy was 21 days (19-32). No grade 3/4 surgical, metabolic, or hematologic complications occurred. In all cases post-operative FDG-PET/CT scan was negative, and after a median time of 10 months (6-37) from SCS + HIPEC no secondary recurrence was observed. Conclusions Minimally invasive SCS + HIPEC can be safely performed in selected ovarian cancer patients with platinum sensitive isolated relapse.

Original languageEnglish
Pages (from-to)303-306
Number of pages4
JournalGynecologic Oncology
Volume132
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Ovarian Neoplasms
Recurrence
Platinum
Robotics
oxaliplatin
Length of Stay
Adjuvant Chemotherapy
Operative Time
Laparoscopy
Cisplatin
Drug Therapy
Skin

Keywords

  • HIPEC
  • Isolated platinum sensitive relapse
  • Laparoscopy
  • Minimally invasive surgery
  • Ovarian cancer
  • Robotic

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Fagotti, A., Petrillo, M., Costantini, B., Fanfani, F., Gallotta, V., Chiantera, V., ... Scambia, G. (2014). Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: A case series. Gynecologic Oncology, 132(2), 303-306. https://doi.org/10.1016/j.ygyno.2013.12.028

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer : A case series. / Fagotti, A.; Petrillo, M.; Costantini, B.; Fanfani, F.; Gallotta, V.; Chiantera, V.; Turco, L. C.; Bottoni, C.; Scambia, G.

In: Gynecologic Oncology, Vol. 132, No. 2, 02.2014, p. 303-306.

Research output: Contribution to journalArticle

Fagotti, A, Petrillo, M, Costantini, B, Fanfani, F, Gallotta, V, Chiantera, V, Turco, LC, Bottoni, C & Scambia, G 2014, 'Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: A case series', Gynecologic Oncology, vol. 132, no. 2, pp. 303-306. https://doi.org/10.1016/j.ygyno.2013.12.028
Fagotti A, Petrillo M, Costantini B, Fanfani F, Gallotta V, Chiantera V et al. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: A case series. Gynecologic Oncology. 2014 Feb;132(2):303-306. https://doi.org/10.1016/j.ygyno.2013.12.028
Fagotti, A. ; Petrillo, M. ; Costantini, B. ; Fanfani, F. ; Gallotta, V. ; Chiantera, V. ; Turco, L. C. ; Bottoni, C. ; Scambia, G. / Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer : A case series. In: Gynecologic Oncology. 2014 ; Vol. 132, No. 2. pp. 303-306.
@article{e3033544d4c743b691485a167fb74b3a,
title = "Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: A case series",
abstract = "Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse received SCS + HIPEC during a 4-year period. Among them, 10 cases (11.9{\%}) showed isolated relapse and were treated with laparoscopic/robotic SCS + HIPEC. In all cases complete debulking was achieved. In HIPEC treatment, 9 women received cisplatin at 75 mg/m2, and the remaining patient oxaliplatin 460 mg/m2. In 7 patients SCS was performed through the laparoscopic route, and in 3 cases with a robotic approach. The median operative time from skin incision to the end of cytoreductive surgery was 122 min (95-140), estimated blood loss was 50 cm3 (50-100), and the median length of hospital stay was 4 days (3-7). The interval from surgery to adjuvant chemotherapy was 21 days (19-32). No grade 3/4 surgical, metabolic, or hematologic complications occurred. In all cases post-operative FDG-PET/CT scan was negative, and after a median time of 10 months (6-37) from SCS + HIPEC no secondary recurrence was observed. Conclusions Minimally invasive SCS + HIPEC can be safely performed in selected ovarian cancer patients with platinum sensitive isolated relapse.",
keywords = "HIPEC, Isolated platinum sensitive relapse, Laparoscopy, Minimally invasive surgery, Ovarian cancer, Robotic",
author = "A. Fagotti and M. Petrillo and B. Costantini and F. Fanfani and V. Gallotta and V. Chiantera and Turco, {L. C.} and C. Bottoni and G. Scambia",
year = "2014",
month = "2",
doi = "10.1016/j.ygyno.2013.12.028",
language = "English",
volume = "132",
pages = "303--306",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer

T2 - A case series

AU - Fagotti, A.

AU - Petrillo, M.

AU - Costantini, B.

AU - Fanfani, F.

AU - Gallotta, V.

AU - Chiantera, V.

AU - Turco, L. C.

AU - Bottoni, C.

AU - Scambia, G.

PY - 2014/2

Y1 - 2014/2

N2 - Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse received SCS + HIPEC during a 4-year period. Among them, 10 cases (11.9%) showed isolated relapse and were treated with laparoscopic/robotic SCS + HIPEC. In all cases complete debulking was achieved. In HIPEC treatment, 9 women received cisplatin at 75 mg/m2, and the remaining patient oxaliplatin 460 mg/m2. In 7 patients SCS was performed through the laparoscopic route, and in 3 cases with a robotic approach. The median operative time from skin incision to the end of cytoreductive surgery was 122 min (95-140), estimated blood loss was 50 cm3 (50-100), and the median length of hospital stay was 4 days (3-7). The interval from surgery to adjuvant chemotherapy was 21 days (19-32). No grade 3/4 surgical, metabolic, or hematologic complications occurred. In all cases post-operative FDG-PET/CT scan was negative, and after a median time of 10 months (6-37) from SCS + HIPEC no secondary recurrence was observed. Conclusions Minimally invasive SCS + HIPEC can be safely performed in selected ovarian cancer patients with platinum sensitive isolated relapse.

AB - Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse received SCS + HIPEC during a 4-year period. Among them, 10 cases (11.9%) showed isolated relapse and were treated with laparoscopic/robotic SCS + HIPEC. In all cases complete debulking was achieved. In HIPEC treatment, 9 women received cisplatin at 75 mg/m2, and the remaining patient oxaliplatin 460 mg/m2. In 7 patients SCS was performed through the laparoscopic route, and in 3 cases with a robotic approach. The median operative time from skin incision to the end of cytoreductive surgery was 122 min (95-140), estimated blood loss was 50 cm3 (50-100), and the median length of hospital stay was 4 days (3-7). The interval from surgery to adjuvant chemotherapy was 21 days (19-32). No grade 3/4 surgical, metabolic, or hematologic complications occurred. In all cases post-operative FDG-PET/CT scan was negative, and after a median time of 10 months (6-37) from SCS + HIPEC no secondary recurrence was observed. Conclusions Minimally invasive SCS + HIPEC can be safely performed in selected ovarian cancer patients with platinum sensitive isolated relapse.

KW - HIPEC

KW - Isolated platinum sensitive relapse

KW - Laparoscopy

KW - Minimally invasive surgery

KW - Ovarian cancer

KW - Robotic

UR - http://www.scopus.com/inward/record.url?scp=84894042827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894042827&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2013.12.028

DO - 10.1016/j.ygyno.2013.12.028

M3 - Article

C2 - 24378877

AN - SCOPUS:84894042827

VL - 132

SP - 303

EP - 306

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -